Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Shares of Immuneering Corporation IMRX were up 5.1% yesterday after the company announced the dosing of the first patient in a pivotal phase III study evaluating its lead product candidate, atebimetinib (IMM-1-104), in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the first-line treatment of metastatic pancreatic cancer.

The global phase III MAPKeeper 301 study will evaluate the safety and efficacy of atebimetinib, a dual MEK inhibitor plus mGnP, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received no prior systemic anti-cancer therapy.

In the MAPKeeper 301 study, patients will be randomized to receive either atebimetinib (320 mg once daily) in combination with mGnP or standard-of-care GnP alone.

The primary endpoint of the study is overall survival (OS), while key secondary endpoints include progression-free survival, overall response rate, disease control rate, safety and tolerability and quality of life.

Top-line data from the MAPKeeper 301 study is expected to be announced in mid-2028.

IMRX Price Performance

Year to date, shares of Immuneering have declined 37.4% compared with the industry’s decrease of 3.3%.Zacks Investment Research

Image Source: Zacks Investment Research

IMRX's Updates on Atebimetinib Development

In January 2026, the company reported positive updated OS and safety data from the phase IIa study arm evaluating atebimetinib plus mGnP for treating first-line pancreatic cancer.

Data from the study showed that the combination of atebimetinib plus mGnP led to a 64% OS at 12 months compared to 35% for the standard of care in the given patient population.

The company is also developing atebimetinib as a monotherapy in third-line pancreatic cancer.

Beyond pancreatic cancer, Immuneering is evaluating atebimetinib in combination with Regeneron's REGN anti-PD-1 therapy, Libtayo (cemiplimab), in a phase II study in patients with first-line RAS-mutant non-small-cell lung cancer (NSCLC). Dosing in the study is expected to begin in the second half of 2026.

In February 2025, Immuneering entered into a collaboration with Regeneron to evaluate atebimetinib in combination with Libtayo for treating NSCLC.

Per this agreement, Immuneering will fund the planned studies while REGN will supply Libtayo, which is approved for multiple cancer indications.

Immuneering Corporation PriceImmuneering Corporation Price

Immuneering Corporation price | Immuneering Corporation Quote

IMRX's Zack Rank & Stocks to Consider

Immuneering currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA and Immunocore IMCR, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Story Continues

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 107.7% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Immuneering Corporation (IMRX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk NVO shares gained 2.7% on Thursday as investors focused on a major regulatory milestone for its obesity franchise, helping offset concerns stemming from NVO's disclosure of an IT security incident. The stock's advance reflected optimism around the U.K. Medicines and Healthcare products Regulatory Agency ("MHRA") approval of the Wegovy pill (oral semaglutide 25mg) for chronic weight management in adults with obesity or overweight and at least one weight-related condition. The therapy is indicated as an adjunct to a reduced-calorie diet and increased physical activity.

The approval makes the United Kingdom the first country in Europe to authorize a daily GLP-1 weight-loss pill, offering patients a convenient non-injectable alternative to weekly obesity treatments, with commercial availability via private prescription expected within weeks. In the United Kingdom, the drug is already approved as a once-weekly injection for reducing major cardiovascular events and easing HFpEF symptoms in obese patients.

Investors viewed the approval as strategically important, marking the third authorization for the Wegovy pill after the United States and the UAE. The oral therapy expands Novo Nordisk's obesity portfolio beyond injectable treatments, helping reach patients who are reluctant to use injections while offering the convenience of a daily pill and the potential for stronger treatment adherence. As the first approved daily GLP-1 weight-loss pill in Europe, the Wegovy pill strengthens Novo Nordisk's position in the fast-growing weight-management market, creating an additional avenue for future growth.

Year to date, NVO shares have lost 13.6% against the industry's 4.5% growth.Zacks Investment Research

Image Source: Zacks Investment Research

The positive regulatory news appeared to outweigh concerns about a cybersecurity incident disclosed by Novo Nordisk on the same day in a separate press release. The company reported unauthorized access to a limited number of internal IT systems and said certain non-public data, including personal information, had been copied externally without authorization. NVO has engaged external cybersecurity experts, notified relevant authorities and implemented containment measures, including temporarily taking some internal systems offline.

While the investigation remains ongoing and the incident could expose the company to regulatory scrutiny, remediation costs and reputational risks, Novo Nordisk stated that its core business operations have not been affected. The market's reaction suggests investors currently view the breach as a manageable operational issue, while assigning greater weight to the long-term commercial significance of Wegovy pill's landmark U.K. approval.

Story Continues

How Effective Is NVO's Wegovy Pill for Obesity?

The MHRA approval of Novo Nordisk's Wegovy pill was primarily based on robust late-stage clinical evidence from the phase III OASIS development program. The global program comprised four studies enrolling about 1,300 patients with obesity. A key 64-week phase IIIb study, OASIS 4, evaluated the efficacy and safety of the Wegovy pill compared to placebo in 307 adults with obesity or overweight with one or more comorbidities.

Results from OASIS 4 demonstrated strong and clinically meaningful weight loss, where obesity patients treated with the Wegovy pill achieved a mean reduction of 16.6% when treatment was adhered to. The magnitude of weight loss was comparable to that of injectable Wegovy 2.4 mg, with one in three patients achieving 20% or greater weight reduction. Importantly, the safety and tolerability profile of oral Wegovy was consistent with prior semaglutide studies, reinforcing confidence in its use. Novo Nordisk also noted that no currently available oral GLP-1 therapy matches the level of weight loss achieved with the Wegovy pill in clinical studies.

Per Novo Nordisk, obesity is a complex chronic disease affecting approximately 15 million people in the United Kingdom, with the prevalence of overweight and obesity among adults projected to reach 71% by 2040. The company emphasized that obesity requires long-term management and that treatment decisions, including the use of pharmacotherapy, should be tailored to individual patients through shared decision-making between healthcare providers and patients.

Novo Nordisk expects the approval and launch of the Wegovy pill in other select markets in the second half of 2026.

Novo Nordisk A/S Price and ConsensusNovo Nordisk A/S Price and Consensus

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote

NVO's Zacks Rank & Stocks to Consider

Novo Nordisk currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA, Indivior Pharmaceuticals INDV and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation's 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 107.7% year to date.

Liquidia Corporation'searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals' 2026 earnings per share have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV shares have gained 6.3% year to date.

Indivior Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore's 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.

Immunocore's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Bayer BAYRY announced that the European Medicines Agency (EMA) has validated the marketing authorization application for its investigational, once-daily, oral Factor XIa inhibitor, asundexian, for the prevention of ischemic stroke in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). This marks the completion of the regulatory application submission process and the beginning of the EMA’s centralized review procedure.

Bayer noted that stroke is an increasing public health challenge, affecting approximately 10 million people in Europe living with its long-term consequences, while more than one million new cases are reported each year. BAYRY added that stroke remains the world's and Europe's second-leading cause of death, placing a substantial burden on healthcare systems, with global costs estimated at $891 billion annually.

Shares of Bayer have lost 6.1% year to date against the industry’s 4.8% growth.Zacks Investment Research

Image Source: Zacks Investment Research

BAYRY’s EU Filing for Asundexian Supported by Phase III Data

Bayer’s marketing application for asundexian to the EMA is supported by encouraging data from the phase III OCEANIC-STROKE study. The study investigated the efficacy and safety of asundexian 50 mg compared to placebo for the prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk TIA in combination with antiplatelet therapy. It enrolled 12,327 patients worldwide.

The primary efficacy endpoint was time to ischemic stroke, and the primary safety endpoint was major bleeding.

Bayer reported that in the OCEANIC-STROKE study, asundexian significantly reduced ischemic stroke by 26% in patients after a non-cardioembolic ischemic stroke or high-risk TIA, compared to placebo, both in combination with antiplatelet therapy, with no increase in the risk of International Society on Thrombosis and Hemostasis major bleeding.

The benefit was consistent across all major patient subgroups, regardless of age, sex, stroke subtype, stroke severity, or background antiplatelet regimen. Asundexian is viewed as a potential blockbuster opportunity in a market where the risk of recurrent stroke remains high.

Bayer is also pursuing broader global regulatory approvals for asundexian. Last month, the FDA accepted BAYRY’s regulatory filing for asundexian to prevent ischemic stroke in patients following a non-cardioembolic ischemic stroke or TIA under its Priority Review pathway, potentially accelerating the regulatory review process in the United States. A filing for the candidate for the same indication is also currently under review in Japan.

Story Continues

In addition to the U.S. and Japan filings, China’s regulatory body also recently accepted Bayer’s marketing authorization application for the therapy to treat the above indication and granted it Priority Review designation.

Bayer Aktiengesellschaft Price and ConsensusBayer Aktiengesellschaft Price and Consensus

Bayer Aktiengesellschaft price-consensus-chart | Bayer Aktiengesellschaft Quote

BAYRY’s Zacks Rank & Other Stocks to Consider

Bayer currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are Liquidia Corporation LQDA, Indivior Pharmaceuticals INDV and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 89.2% year to date.

Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV shares have gained 6.1% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 19.6% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Shares of Kymera Therapeutics KYMR rose 4% after the company announced the initiation of patient dosing in the first-in-human phase I study of KT-485 (SAR447971), an investigational oral IRAK4 protein degrader being developed in partnership with Sanofi SNY.

The study is evaluating KT-485 in healthy adult volunteers and patients with hidradenitis suppurativa (HS), marking the program's transition into clinical development. This triggered a $20 million milestone payment from Sanofi to Kymera under the companies’ collaboration agreement. The study will assess the candidate’s safety, tolerability, pharmacokinetics and exploratory biomarkers through single-ascending-dose, multiple-ascending-dose and open-label multiple-dose cohorts.

Year to date, shares of KYMR have lost 1.1% compared with the industry’s 3.1% decline.Zacks Investment Research

Image Source: Zacks Investment Research

Terms of the Sanofi Deal for KT-485

Under the collaboration agreement, SNY is responsible for development, regulatory and commercialization activities associated with KT-485, while Kymera remains eligible for up to $975 million in potential development, regulatory and commercial milestone payments. KYMR also retains the option to participate in future U.S. development and commercialization efforts, including a 50/50 profit-sharing arrangement in the United States and is eligible for tiered double-digit royalties on sales in international markets.

More on Kymera’s KT-485

KT-485 is a second-generation oral degrader designed to eliminate IRAK4, a key protein involved in inflammatory and immune signaling pathways. IRAK4 plays a central role in the myddosome complex, which transmits signals from IL-1 and toll-like receptors that drive inflammation. By degrading the entire IRAK4 protein, KT-485 has the potential to provide a broader anti-inflammatory effect than traditional inhibitors.

In preclinical studies, KT-485 demonstrated greater potency, improved selectivity and a more favorable safety profile than the earlier IRAK4 degrader candidate, KT-474. These results led Sanofi to prioritize KT-485 for clinical development and discontinue KT-474, a decision that triggered a $20 million milestone payment to Kymera in 2025.

KYMR’s Zacks Rank & Stock to Consider

Kymera currently carries a Zacks Rank #3 (Hold).

Two better-ranked stocks in the biotech sector are Indivior Pharmaceuticals INDV and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.6% year to date.

Story Continues

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.94. Over the same period, EPS estimates for 2027 have risen to $4.81 from $3.79. LQDA shares have surged 85.6% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Johnson & Johnson hat angekündigt, dass es eine definitive Vereinbarung zur Übernahme des kalifornischen Biotechnologieunternehmens Firefly Bio für 1 Milliarde US-Dollar in bar geschlossen hat. Durch die Übernahme wird das Firelink-Abbauplatfom von Firefly Bio zu JNJ's Pipeline hinzugefügt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investing.com -- Die Marvell-Technologie Inc (NASDAQ:MRVL) hat einen starken zweitägigen Rückgang in der Nachhandelsphase am Freitag abgeschwächt, nachdem die Ankündigung ihrer bevorstehenden Aufnahme in den S&P 500-Index bekannt gegeben wurde. Die Aktien des Halbleiterunternehmens stiegen um 6% höher im Nachhandel, als S&P Dow Jones Indices die Änderungen für ihre quartalsweise Rebalancierung offenbarte.

Die Indexaufnahme markiert einen starken und volatilen Wochenabschluss für Marvell, das zunächst nach dem Ausspruch von Nvidia-CEO Jensen Huang über eine mögliche Billionen-Dollar-Aktie am Dienstag aufstieg. Der Marktenthusiasmus wurde noch verstärkt, als Stifel sein Kursziel auf 321,00 $ (von 230,00 $) erhöhte, wobei Analyst Tore Svanberg den Computex-Keynote von CEO Matt Murphy als "eine hochproduzierte Bestätigung der Daten-Infrastruktur-These bezeichnet, die wir für einige Zeit unterzeichnet haben, und sie passte sauber mit dem finanziellen Verlauf zusammen, den das Management am letzten F1Q27-Anruf vorgestellt hat."

Allerdings wurde der Halbleiter-Sektor durch die Earnings-Ergebnisse von Broadcom am Donnerstag enttäuscht. Die Gewinnabspauschung zog Marvell-Aktien in den regulären Handelsstunden des Freitags um 16,7% nach unten, obwohl der Rückgang nicht die 28,5%-ige Gesamtgewinngewinnmarke auslöste.

Die Wall Street sieht nun die Aufnahme von Marvell in den S&P-500 als Katalysator für das Fortbestehen des Bullenmomentums des Unternehmens. Die Aufnahme in den weltweit wertvollsten Aktienindex erzwingt eine bedeutende Steigerung der Unternehmen, da Index-tracking-Fonds gezwungen sind, die Aktien zu kaufen und breitere institutionelle Unterstützung einladen.

Die Manufacturing-Lösungsunternehmen Flex Ltd (NASDAQ:FLEX) ist ebenfalls dem Benchmark-Index beigetreten und seine Aktien stiegen um 4% im Nachhandel. Die beiden neuen Technologieunternehmen werden offiziell Pool Corporation (NASDAQ:POOL) und Campbell’s Co (NASDAQ:CPB) vor der Eröffnung des Handels am Montag, den 22. Juni, ersetzen.

Nach der Ankündigung fielen die Aktien von Pool um 1,2% in der Spätphase, während die Aktien von Campbell's relativ unverändert blieben. Beide Unternehmen werden aus dem S&P-500 in den S&P SmallCap 600 Index absteigen, um sicherzustellen, dass die Benchmarks ihre jeweiligen Marktkapitalisierungsrange repräsentieren.

Die breitere Indexumstellung wird auch den S&P MidCap 400 treffen, wobei Namen wie Roku Inc (NASDAQ:ROKU), Coeur Mining Inc (NYSE:CDE) und Semtech Corporation (NASDAQ:SMTC) dem Index beitreten werden. Gleichzeitig werden Unternehmen wie Warby Parker Inc (NYSE:WRBY) und Liquidia Technologies Inc (NASDAQ:LQDA) in den S&P SmallCap 600 aufgenommen, während unterperformende Konstituente wie Gogo und Vital Farms entfernt werden.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Aufgrund der angespannten Situation im Nahen Osten und dem daraus resultierenden Marktvolatilität empfehlen sich Aktien mit niedriger Beta-Wert. Liquidia Corporation (LQDA), Chevron Corporation (CVX), Occidental Petroleum (OXY) und Valero Energy Corporation (VLO) könnten von Investoren in den Fokus genommen werden. Die Beta-Wert eines Stocks misst die Volatilität oder das Risiko eines bestimmten Assets im Vergleich zum Markt. Ein Wert von 1 bedeutet, dass der Preis des Stocks mit dem Markt bewegt wird. Wenn der Beta-Wert größer als 1 ist, ist der Stock mehr volatil als der Markt. Die vier genannten Unternehmen erfüllen die Kriterien: niedriger Beta-Wert (zwischen 0 und 0,6), positive Preisentwicklung in den letzten 4 Wochen, hoher Handelsvolumen und Zacks-Rang 1.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investoren, die zwischen Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) und State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) wählen, können die geringeren Kosten und breitere Diversifikation von IBBQ gegenüber der etablierten Größe und pharmazeutischen Ausrichtung von XPH abwägen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Gilead Sciences, Inc. (GILD) hat positive Ergebnisse aus der spät-stufigen IDEAL-Studie in Patienten mit primärer bilärer Cholangitis (PBC) vorgestellt. Die Studie zeigte, dass Livdelzi (Seladelpar) die Proportionszahl der Patienten erhöht hat, die nach 52 Wochen eine Normalisierung der alkalischen Phosphatase (ALP) erreicht haben, im Vergleich zum Placebo.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Merck hat bekannt gegeben, dass die FDA der investigativen oralen spezifischen KRAS G12C-Hemmer calderasib (MK-1084) die Bezeichnung als Breakthrough-Therapie für das Behandeln bestimmter Patienten mit neu diagnostiziertem metastatischem KRAS G12C-mutanten nicht kleinen Zellkarzinom (NSCLC) erteilt hat.